Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
clinical heterogeneity of primary cutaneous t cell lymphoma a 20 year single institution experience
Original title: “Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.”
brentuximab vedotin in cutaneous t cell lymphoma emerging evidence and therapeutic insights for cd30 negative and cd30 low disease
Original title: “Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease.”
CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access. And that's really done through sequential clinical trials, understanding of medicine, where it works, where it doesn't, how safe it is, then building on that. Kristie L. Kahl: What are some of the current challenges that we still see with this disease that warrants further research? Dr. Steven M. Horwitz: The big challenge is most of our therapies to date. And then a generation of those that don't use a person's own T cells, different strategies, either another person’s cells, non–T-cell therapies. I think those are going to be tested in early-phase clinical trials now into the next year or two. I have some optimism that that we may find some areas where those are quite effective. Kristie L. Kahl: What do patients with this disease have to look forward to? Steven M. Horwitz: There's a lot going on, despite it being a rare disease. And I think most of the research is really aimed at understanding better therapies or developing better therapies and understanding how to better match them to patients most likely to benefit, not match them with patients least likely to benefit. I think there's a lot of energy looking at new therapies, and they're really focused on more potent and safer therapies. So, I think the optimism would be that there's a lot of people working on this. There are some real strategies there that may change things for the future. We have to work with each other and our patients to do the hard work of understanding those treatments, understanding how best and safely to use them. But there is sort of a broad, really international concerted effort to attack these diseases.
Original title: “Clinical Trials in Cutaneous T-Cell Lymphoma | CURE”
development and preliminary validation of the ctcl pro 20 a novel quality of life survey for patients with cutaneous t cell lymphoma
Original title: “The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma.”
targeting cutaneous t cell lymphoma in non hodgkin lymphoma what s new for investigational agents
Original title: “Targeting Cutaneous T-cell lymphoma in non-hodgkin lymphoma: What's new for investigational agents?”